EPISODE · Mar 19, 2026 · 13 MIN
From London: Spur Therapeutics is an a phase 3 for its gene therapy for Gaucher Disease - using a unique construct that allows them to have a lower dose than other gene therapies
from BiotechTV - News · host BiotechTV
CEO Michael Parini describes the science behind how Spur's gene therapies have two key differences compared to others, including a proprietary capsid. He discusses phase 1/2 data that has already been announced, and how he thinks about the phase 3.
What this episode covers
CEO Michael Parini describes the science behind how Spur's gene therapies have two key differences compared to others, including a proprietary capsid. He discusses phase 1/2 data that has already been announced, and how he thinks about the phase 3.
NOW PLAYING
From London: Spur Therapeutics is an a phase 3 for its gene therapy for Gaucher Disease - using a unique construct that allows them to have a lower dose than other gene therapies
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m